Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

Open access
Atmaca, A, Al-Batran, S-E, Maurer, A, Neumann, A, Heinzel, T, Hentsch, B, Schwarz, S E, Hövelmann, S, Göttlicher, M, Knuth, A, Jäger, E·2007·British Journal of Cancer

Abstract

Altered histone deacetylase (HDAC) activity has been identified in several types of cancer. This study was designed to determine the safety and maximum tolerated dose (MTD) of valproic acid (VPA) as an HDAC inhibitor in cancer patients. Twenty-six pre-treated patients with progressing solid tumours were enrolled in dose-escalating three-patient cohorts, starting at a dose of VPA 30 mg kg(-1) day(-1). VPA was administered as an 1-h infusion daily for 5 consecutive days in a 21-day cycle. Neurocognitive impairment dominated the toxicity profile, with grade 3 or 4 neurological side effects occurring in 8 out of 26 patients. No grade 3 or 4 haematological toxicity was observed. The MTD of infusional VPA was 60 mg kg(-1) day(-1). Biomonitoring of peripheral blood lymphocytes demonstrated the induction of histone hyperacetylation in the majority of patients and downmodulation of HDAC2. Pharmacokinetic studies showed increased mean and maximum serum VPA concentrations >120 and >250 mg l(-1), respectively, in the 90 and 120 mg kg(-1) cohorts, correlating well with the incidence of dose-limiting toxicity (DLT). Neurotoxicity was the main DLT of infusional VPA, doses up to 60 mg kg(-1) day(-1) for 5 consecutive days are well tolerated and show detectable biological activity. Further investigations are warranted to evaluate the effectivity of VPA alone and in combination with other cytotoxic drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6603851

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 183

Metadata

Authors
Atmaca, A., Al-Batran, S.-E., Maurer, A., Neumann, A., Heinzel, T., Hentsch, B., Schwarz, S. E., Hövelmann, S., Göttlicher, M., Knuth, A., & Jäger, E.
Venue
British Journal of Cancer
Published
2007-06-19
Volume
97
Issue
2
Pages
177-182
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2071888464
Cited by
183
References
2
FWCI
6.94
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. https://app.cochat.ai/papers/10.1038/sj.bjc.6603851
The paper
Atmaca, A., Al-Batran, S.-E., Maurer, A., Neumann, A., Heinzel, T., Hentsch, B., Schwarz, S. E., Hövelmann, S., Göttlicher, M., Knuth, A., & Jäger, E. (2007). Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6603851

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.